New York-based Turing Pharmaceuticals has appointed Eliseo Salinas as president of research and development.
Salinas has played a leading role in numerous programmes for a range of diseases and disorders, with specific focus on central nervous systems (CNS) condition such as depression and anxiety, schizophrenia, epilepsy, stroke, Parkinson’s, attention deficit disorder and Alzheimer’s disease.
Commenting on his new role, Salinas said: “I am excited to be joining Turing. It is a special opportunity to be part of a dynamic young company with an important portfolio of assets in development, a strong management team and a great vision.
“I look forward to helping to accelerate Turing’s success and contribution to healthcare.”
He joins from Relmada Therapeutics, where he served as president and chief scientific officer in addition to holding the role of head of R&D.
Prior to that, Salinas held multiple senior medical and science positions at biopharma companies including Elan Pharmaceuticals, Adolor and Shire, where he served as chief scientific officer.
Martin Shkreli, founder and chairman of Turing, added: “We are pleased to welcome Eliseo Salinas to our leadership team.
“Eliseo combines proven capabilities to bring important new treatments to patients and their physicians, with a deep understanding of the patient and physician communities. His appointment is another major step as we build Turing’s capabilities for the long term, advance our existing pipeline and work to create and acquire new assets.”